Gilead terminates study of GS-3583 due to safety assessment

A post to the clinicaltrials.gov website last updated on December 5 states that sponsor Gilead Sciences terminated a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583 in participants with advanced solid tumors. The study, which was intended to characterize the safety and tolerability of GS-3583 as monotherapy, and to determine the maximum tolerated dose or recommended Phase 2 dose of GS-3583 as monotherapy in participants with advanced solid tumors, was terminated due to a "sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule," according to the post. Reference Link